PET imaging of STING expression in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and effectiveness of a novel 68Ga-labeled agonist, [68Ga]Ga-Sa-DABI-4, for noninvasive positron emission tomography (PET) imaging of the stimulator of interferon gene (STING) expression in tumors. By monitoring STING expression, the study aims to enhance the understanding of STING therapy in cancer treatment. Participants will include adults with suspected or diagnosed malignant diseases, and the study will assess the biodistribution of the imaging agent in the tumor microenvironment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. At least 18 years of age.
2. Signed informed consent.
3. Patients with suspected or newly diagnosed or previously malignant disease.

Exclusion Criteria:

1. Patients with non-malignant disease.
2. Patients with pregnancy.
3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
4. Known or expected hypersensitivity to \[68Ga\]Ga-Sa-DABI-4 or any of its components.
5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.

Where it's running

• The First Affiliated Hospital of Chongqing Medical University
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Xiaoyang Zhang, PhD
• Email: zhangxy@mail.bnu.edu.cn
• Phone: 023-89011755

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults

  This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07618936

• FAPI-PET/CT imaging for diagnosing and staging pancreatic cancer

  This study will try 18F‑FAPI‑74 PET/CT scans in adults with suspected or recurrent pancreatic cancer to see if they detect lymph node spread and distant metastases more accurately.

  Recruiting Phase 2/3 Turku University Hospital · Turku · NCT07098598

• Establishing a cohort for Alzheimer's disease research in China

  This study is trying to understand how brain scans and other health markers relate to Alzheimer's disease in both people with and without cognitive issues in China, to help find ways to detect and prevent the disease early.

  Recruiting Huashan Hospital · Shanghai · NCT06827678

• Using PET/CT imaging to diagnose GLP-1 receptor related diseases

  This study is testing a special imaging scan to see if it can help doctors better diagnose cancer in adults who may have diseases related to GLP-1 receptors.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06725693

• Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients

  This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690970

• Evaluating PET/CT for SSTR-related diseases

  This study is testing a new type of PET/CT scan to see if it can help find cancer spots in adults who have tumors related to SSTR diseases.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690957

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.